These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Highly specific urine-based marker of bladder cancer. Van Le TS; Miller R; Barder T; Babjuk M; Potter DM; Getzenberg RH Urology; 2005 Dec; 66(6):1256-60. PubMed ID: 16360453 [TBL] [Abstract][Full Text] [Related]
5. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer. Kumar A; Kumar R; Gupta NP Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358 [TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors. Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289 [TBL] [Abstract][Full Text] [Related]
7. Identification of nuclear matrix protein alterations associated with human colon cancer. Brünagel G; Vietmeier BN; Bauer AJ; Schoen RE; Getzenberg RH Cancer Res; 2002 Apr; 62(8):2437-42. PubMed ID: 11956108 [TBL] [Abstract][Full Text] [Related]
8. Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction. Christoph F; Müller M; Schostak M; Soong R; Tabiti K; Miller K Urology; 2004 Jul; 64(1):157-61. PubMed ID: 15245962 [TBL] [Abstract][Full Text] [Related]
9. Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer. Konety BR; Nguyen TS; Brenes G; Sholder A; Lewis N; Bastacky S; Potter DM; Getzenberg RH J Urol; 2000 Sep; 164(3 Pt 1):634-9. PubMed ID: 10953114 [TBL] [Abstract][Full Text] [Related]
10. [Clinical evaluation of urinary NMP22 (nuclear matrix protein 22) bladder chek in the detection of patients with bladder cancer]. Kitsukawa S; Yamamoto Y; Hosoda S; Otsuru N; Matsumoto T; Matsumoto T; Aizawa T; Noda K; Ito T Hinyokika Kiyo; 2006 Mar; 52(3):167-72. PubMed ID: 16617867 [TBL] [Abstract][Full Text] [Related]
11. Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors. Di Carlo A; Terracciano D; Mariano A; Macchia V Oncol Rep; 2006 May; 15(5):1321-6. PubMed ID: 16596205 [TBL] [Abstract][Full Text] [Related]
12. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker. Nouraee N; Mowla SJ; Ozhand A; Parvin M; Ziaee SA; Hatefi N Urol J; 2009; 6(2):101-8. PubMed ID: 19472128 [TBL] [Abstract][Full Text] [Related]
13. [Efficacy of detection of specific nuclear protein of matrix 22 in the urine in diagnosis of urinary bladder cancer]. Darenkov SP; Perlin DV; Chernyshev IV; Parshina VN; Ivanov AV; Iarovoĭ SK Urologiia; 2006; (6):48, 49-51. PubMed ID: 17315713 [TBL] [Abstract][Full Text] [Related]
14. [Clinical evaluation of urinary nuclear matrix protein 22 as a marker for bladder cancer]. Kurokawa S; Morita T; Muraishi O; Tokue A Hinyokika Kiyo; 2001 Apr; 47(4):247-50. PubMed ID: 11411098 [TBL] [Abstract][Full Text] [Related]
15. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer. Bowles L; Bialkowska-Hobrzanska H; Bukala B; Nott L; Razvi H Can J Urol; 2004 Dec; 11(6):2438-44. PubMed ID: 15636669 [TBL] [Abstract][Full Text] [Related]
16. An office-based immunodiagnostic assay for detecting urinary nuclear matrix protein 52 in patients with bladder cancer. Attallah AM; Sakr HA; Ismail H; Abdel-Hady el-SK; El-Dosoky I BJU Int; 2005 Aug; 96(3):334-9. PubMed ID: 16042726 [TBL] [Abstract][Full Text] [Related]
17. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Urakami S; Shiina H; Enokida H; Kawakami T; Kawamoto K; Hirata H; Tanaka Y; Kikuno N; Nakagawa M; Igawa M; Dahiya R Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2109-16. PubMed ID: 16609023 [TBL] [Abstract][Full Text] [Related]
18. Comparison of seven screening methods in the diagnosis of bladder cancer. Sun Y; He DL; Ma Q; Wan XY; Zhu GD; Li L; Luo Y; He H; Yang L Chin Med J (Engl); 2006 Nov; 119(21):1763-71. PubMed ID: 17097029 [TBL] [Abstract][Full Text] [Related]
19. Mechanistic analysis of the role of BLCA-4 in bladder cancer pathobiology. Myers-Irvin JM; Van Le TS; Getzenberg RH Cancer Res; 2005 Aug; 65(16):7145-50. PubMed ID: 16103064 [TBL] [Abstract][Full Text] [Related]
20. Screening and monitoring for bladder cancer: refining the use of NMP22. Ponsky LE; Sharma S; Pandrangi L; Kedia S; Nelson D; Agarwal A; Zippe CD J Urol; 2001 Jul; 166(1):75-8. PubMed ID: 11435827 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]